OncLive TV

Naveen Pemmaraju, MD, discusses the characteristics of disease progression in patients with myelofibrosis.

Michael J. Mauro, MD, discusses managing symptom burden in patients with myelofibrosis.

Sameem Abedin, MD, discusses the safety and efficacy of ibrutinib in the treatment of patients with chronic lymphocytic leukemia.

John P. Leonard, MD, discusses the potential for combination regimens with PI3K inhibitors in follicular lymphoma.

Brad S. Kahl, MD, discusses selecting between PI3K inhibitors in follicular lymphoma.

Joleen M. Hubbard, MD, discusses the utility of minimal residual disease assessment for stage II colorectal cancer.

Jimmy Hwang, MD, discusses considerations for second-line treatment in gastric/gastroesophageal junction cancer.

Nicole O. Williams, MD, discusses the role of PI3K inhibitors in hormone receptor–positive, HER2-negative breast cancer.

Faith E. Davies, MD, discusses the next steps for CAR T-cell therapy in the treatment of patients with relapsed/refractory multiple myeloma.

Julian Adams, PhD, discusses research efforts surrounding GDA-201, including details of the cryo buffer that the company developed in order to efficiently freeze and recover the GDA-201 cells.

Julian Adams, PhD, discusses approaches to cell therapy, and the potential of omidubicel as an alternative to bone marrow transplant in leukemias and lymphomas.

Sikander Ailawadhi, MD, discusses the next steps with lisaftoclax in chronic lymphocytic leukemia.

John C. Byrd, MD, discusses future directions with acalabrutinib in chronic lymphocytic leukemia.

Paul M. Barr, MD, discusses the rationale for the long-term analysis of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Omar Nadeem, MD, discusses the integration of isatuximab-irfc in relapsed/refractory multiple myeloma.

Paolo Ghia, MD, PhD, discusses the rationale for the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.

Kamran A. Ahmed, MD, discusses the need for multidisciplinary care in patients with HER2-positive breast cancer and leptomeningeal disease.

Barbara Burtness, MD, discusses the efficacy of immune checkpoint inhibitors in the treatment of patients with head and neck cancer.

Rondell Graham, MBBS, discusses utilizing biomarkers to guide treatment for patients with intrahepatic cholangiocarcinoma.

Amy B. Heimberger, MD, discusses the variability of responses in glioblastoma.

Stephanie E. Weiss, MD, FASTRO, discusses selecting optimal radiation therapy for patients with brain metastases.

Sikander Ailawadhi, MD, discusses the safety profile of lisaftoclax in chronic lymphocytic leukemia.

Balazs Halmos, MD, discusses the efficacy of the COVID-19 vaccines in patients with cancer.

Hussein A. Tawbi, MD, PhD, discusses the safety profile of relatlimab plus nivolumab in advanced melanoma.

Aditya Bardia, MD, MPH, discusses the rationale for the ongoing phase 3 AMEERA-5 trial in estrogen receptor–positive, HER2-negative breast cancer.

Alison Schram, MD, discusses the results of the phase 1/2 eNRGy trial, which were presented during the 2021 ASCO Annual Meeting, in NRG1 fusion–positive solid tumors.

Ruben A. Mesa, MD, discusses the unique characteristics of pacritinib in the treatment of patients with myelofibrosis.

Bassam Sonbol, MD, discusses the role of pembrolizumab in the treatment of patients with gastric cancer.

Jyoti Malhotra, MD, MPH, discusses the safety profile of plinabulin in combination with nivolumab and ipilimumab in relapsed/refractory small cell lung cancer.

Peter Martin, MD, discusses the findings of a real-world analysis of clinical outcomes in mantle cell lymphoma.